Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

Introducing the ‘Better Quality, Better Serviced” Video Conferencing Platform

(Click image to play video) Simplified video conferencing across any device means exceptional usability. Enhanced security settings ensure continuous meeting time, encryption, role-based security and password protection. Introducing Fuzion – providing one integ...

Target Price Raised on 'One of the Highest-Quality Stories' in Oil & Gas

The changes made and the reasons for them are detailed in a Raymond James report. In an Oct. 8 research note, analyst Justin Jenkins reported that Raymond James raised its target price on Phillips 66 (PSX:NYSE) to $120 per share from $117 "on higher conviction in ea...

This Canadian Biopharmaceutical Co. is a Pioneer of the Medical Cannabis Industry

An evidence-based, scientific approach is how Avicanna Inc. ( TSX.AVCN , OTC: AVCNF , Forum ) gains its competitive advantage in the medical cannabis sector. The Canadian biopharmaceutical company has spent over four years in research & development before creating its m...

Aurora Cannabis, EXMceuticals, Tilray - Cannabis development in Portugal

From the street to the clinic. Cannabis had the image of an illegal street drug in most rich countries since the prohibition in the USA in the 1930s. Although cannabis has been used as a medicinal plant for more than 1,000 years, the past decades have been marked by other phar...

Maiden Resource Estimate for North Carolina Lithium Project 'Demonstrates the Quality of the Deposit

The quantified resource and upcoming stock catalysts were provided in a ROTH Capital Partners report. In a April 24 research note, ROTH Capital Partners analyst Joe Reagor reported that Piedmont Lithium Ltd.'s (PLL:NASDAQ; PLL:ASX) just-released initial re...

Coverage Initiated on Producer of Hemp-Derived Cannabidiol Products

A ROTH Capital Partners report presented the reasons for investing in this company. In a March 7 research note, analyst Scott Fortune reported that ROTH Capital Partners initiated coverage on Charlotte's Web Holdings Inc. (CWEB:CSE; CWBHF:OTCQX) with a Buy rating and ...

Medcolcanna Prepares For Recurring Commercial Shipments

An Operational Update for 2021 as The Company Prepares for Recurring Shipments Medcolcanna Organics Inc. (NEO: MCCN), a leading Colombian and globally integrated cannabis company, is providing the following corporate update. Key highlights include: Capacity &...

Biotech 'Thinking Several Steps Ahead with Optimizing IVR Quality Control

The company's latest science, presented at a recent conference, is discussed in a ROTH Capital Partners report. In a July 31 research note, ROTH Capital Partners analyst Yasmeen Rahimi reported that Daré Bioscience Inc. (DARE:NASDAQ) presented two posters o...

Solving the Hemp Extraction Problem created by the US Farm Bill

A CONVERSATION WITH NICK KIMBALL, PRESIDENT AND CEO, CASCADIA EXTRACTS, and AARON WILLIAMS, EXECUTIVE VICE PRESIDENT, CASCADIA EXTRACTS MOTIVATION What was your motivation to enter the hemp market in 2019? KIMBALL : Two years ago, the cannabis market ...

Two Approvals Underscore Biotech's Pipeline Quality

The green lights and their implications are discussed in an H.C. Wainwright & Co. report. In a Jan. 22 research note, H.C. Wainwright & Co. analyst Ram Selvaraju reported that the European Commission approved the regimen consisting of Genmab A/S' (GMAB:NASD...
1 2 3 4 5 6 7 8 9 10 ...